- MapLight dives despite positive data for schizophrenia drugShares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.
- Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEOMost recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy E…